Valuation: DexCom, Inc.

Market Cap 32.54B 28.92B 26.96B 24.58B 46.35B 3,134B 46.8B 327B 127B 1,598B 122B 120B 5,136B P/E 2026 *
34.6x
P/E 2027 * 29.2x
Enterprise Value 31.78B 28.25B 26.33B 24B 45.27B 3,060B 45.7B 319B 124B 1,561B 119B 117B 5,016B EV / Sales 2026 *
6.08x
EV / Sales 2027 * 5.43x
Free-Float
91.27%
Yield 2026 *
-
Yield 2027 * -
1 day-0.52%
1 week-0.52%
Current month+0.79%
1 month-2.55%
3 months+21.66%
6 months+40.52%
Current year+33.19%
1 week 75.8
Extreme 75.8
77.2
1 month 71.8
Extreme 71.8
78.8
Current year 48.8
Extreme 48.8
79.6
1 year 47
Extreme 47
79.6
3 years 47
Extreme 47
131.78
5 years 47
Extreme 47
145.65
10 years 47
Extreme 47
145.65
Manager TitleAgeSince
Chief Executive Officer 47 2025-12-31
Director of Finance/CFO 46 2021-03-18
Chief Tech/Sci/R&D Officer - 2024-04-30
Director TitleAgeSince
Chairman 68 2018-07-29
Director/Board Member 67 2009-11-19
Director/Board Member 47 2025-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.52%-0.52% - - 32.54B
+0.84%-3.53%-26.95%+0.67% 167B
-0.07%-2.41%-8.89%+10.23% 111B
+0.90%+2.11%-24.36%+0.79% 105B
-1.24%-1.31%-48.43%-13.54% 74.82B
-0.24%-0.26%-0.87%+71.72% 59.11B
-0.86%+4.49%+17.49%+57.78% 51.8B
-0.71%-1.36%-7.41%-31.61% 48.5B
+0.12%+0.97%-16.40%+18.55% 40.79B
-1.01%-2.41%+29.18%-8.51% 32.54B
Average -0.36%-0.16%-9.63%+11.79% 76.68B
Weighted average by Cap. -0.25%-0.91%-15.78%+9.41%

Financials

2026 *2027 *
Net sales 5.23B 4.65B 4.33B 3.95B 7.45B 504B 7.52B 52.52B 20.36B 257B 19.63B 19.21B 825B 5.8B 5.16B 4.81B 4.38B 8.26B 559B 8.34B 58.24B 22.57B 285B 21.77B 21.3B 915B
Net income 974M 866M 807M 736M 1.39B 93.83B 1.4B 9.78B 3.79B 47.85B 3.66B 3.58B 154B 1.15B 1.02B 952M 868M 1.64B 111B 1.65B 11.54B 4.47B 56.42B 4.31B 4.22B 181B
Net Debt -761M -677M -631M -575M -1.08B -73.3B -1.09B -7.64B -2.96B -37.38B -2.86B -2.8B -120B -1.06B -943M -879M -802M -1.51B -102B -1.53B -10.66B -4.13B -52.13B -3.98B -3.9B -168B
Logo DexCom, Inc.
DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals. The United States accounts for 71.5% of net sales.
Employees
11,050
Date Price Change Volume
26-10-02 €76.40 -0.52% 78
26-10-01 €76.80 +1.32% 0
26-09-30 €75.80 0.00% 0
26-09-29 €75.80 -0.79% 15
26-09-28 €76.40 -0.26% 25
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
85.36USD
Average target price
95.08USD
Spread / Average Target
+11.39%

Quarterly revenue - Rate of surprise